The heart mainly expresses THRα isoform and the liver expresses THRβ, therefore, it was critical to generate a THRβ specific agonist (179) Clinical studies in future will reveal how the drug can prevent CVD associated with MASLD. The gene discussed is THRA; the disease is metabolic dysfunction-associated steatotic liver disease.